Rare Hemophilia Factors Market by Type and Treatment - Global Industry Analysis and Forecast to 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 90 Pages

Description

Industry Outlook and Trend Analysis

The Rare Hemophilia Factors Market was worth USD 0.23 million in 2014 and is expected to reach approximately USD 0.33 million by 2023, while registering itself at a compound annual growth rate (CAGR) of 4.06% during the forecast period. The market is anticipated to grow at a tremendous CAGR amid the gauge time frame. Numerous new factors concentrates securing endorsements from administrative bodies, for example, the U.S. FDA and government activities focused at expanding diagnosis and treatment rates are among the key patterns boosting the market growth. With expanding R&D exercises by key market players the market is observing a spike in the quantity of new factor concentrates. In recent past, many concentrates have gotten promoting approvals from administrative bodies. Government activities and orders have additionally expanded patient and professional awareness about the rare hemophilia coagulation issue, thereby revving up determination and treatment rates of this condition.

Type Outlook and Trend Analysis

Based on type, the market is fragmented into I, II, V, VII, X, XI, and XIII deficiencies. Awareness about rare hemophilia deficiencies is foreseen to increase over the figure time frame, because of initiatives taken by associations, for example, the World Federation of Hemophilia (WFH) for patient advocacy and enhancing finding and treatment of rare hemophilia disorders. The F-VII deficiency section held the biggest share in the market in 2016. The section is assessed to keep up its position, ascending at the most astounding CAGR amid the estimate time frame.

Treatment Outlook and Trend Analysis

Based on treatment, the rare hemophilia market is portioned into factor concentrates, cryoprecipitate, fresh frozen plasma, and others. The others fragment contains prothrombin complex think (PCC), antifibrinolytic, and desmopressin drugs. The fresh frozen plasma section held the biggest share in 2016. Fresh frozen plasma contains all clotting components and blood proteins. Because of restricted accessibility and affordability of factor concentrates, fresh frozen plasma is used routinely to manage bleeding episodes in rare hemophilia deficiencies.

Regional Outlook and Trend Analysis

North America held the biggest share of the market in 2016. Government activities to expand the rate of diagnosis & reduce treatment expenses, research exercises to enhance management of rare hemophilia conditions, and solid presence of key players a portion of the components supplementing the development of the area. Asia Pacific is anticicpated to encounter the most elevated development over the gauge time frame inferable from developing populace and rising occurrence of autosomal recessive disorders due to consanguineous relational unions in nations, for example, India, Pakistan, and China.

Competitive Insights

The leading players in the market are CSL Behring, Bayer HealthCare Pharmaceuticals LLC, Baxalta, Biogen, Pfizer, Bio Products Laboratory and Novo Nordisk. Many Key players are depending on methods, for example, agreements & joint ventures, collaborations, and advancements to build the visibility of their products and fortify their product portfolios. For example, in January 2015, Novo Nordisk donated USD 3 million to their Hemophilia Foundation as a way to give financial help and upgrade access to hemophilia treatment.

The Rare Hemophilia Factors Market is segmented as follows-

By Type:


Factor I
Factor II
Factor V
Factor VII
Factor X
Factor XI
Factor XIII


By Application:


Fresh Frozen Plasma
Cryoprecipitate
Factor Concentrates
Others


By Region


North America


U.S.
Canada
Mexico







Europe


Germany
UK
France
Russia
Italy
Rest of Europe







Asia-Pacific


China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific







South America


Brazil
Argentina
Columbia
South Africa
Rest of South America







Middle East and Africa


Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA




Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023`
What will be the industry market growth from 2015 to 2023`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising Adoption of Prophylaxis Treatment
3.2.1.2. Favorable Government Initiatives and Mandates
3.2.2. Restraints
3.2.2.1. Low Adoption Rate of New Products Launched
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2014-2023)
4.1.2. Canada Market States and Outlook (2014-2023)
4.1.3. Mexico Market States and Outlook (2014-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2014-2023)
4.2.2. France Market States and Outlook (2014-2023)
4.2.3. UK Market States and Outlook (2014-2023)
4.2.4. Russia Market States and Outlook (2014-2023)
4.2.5. Italy Market States and Outlook (2014-2023)
4.2.6. Rest of Europe Market States and Outlook (2014-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2014-2023)
4.3.2. Japan Market States and Outlook (2014-2023)
4.3.3. Korea Market States and Outlook (2014-2023)
4.3.4. India Market States and Outlook (2014-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2014-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2014-2023)
4.4.2. Argentina Market States and Outlook (2014-2023)
4.4.3. Columbia Market States and Outlook (2014-2023)
4.4.4. Rest of South America Market States and Outlook (2014-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2014-2023)
4.5.2. UAE Market States and Outlook (2014-2023)
4.5.3. Egypt Market States and Outlook (2014-2023)
4.5.4. Nigeria Market States and Outlook (2014-2023)
4.5.5. South Africa Market States and Outlook (2014-2023)
4.5.6. Rest of MEA Market States and Outlook (2014-2023)
5. Rare Hemophilia Factors Market, By Type
5.1. Introduction
5.2. Global Rare Hemophilia Factors Sales, Revenue and Market Share by Type (2014-2018)
5.2.1. Global Rare Hemophilia Factors Sales and Sales Share by Type (2014-2018)
5.2.2. Global Rare Hemophilia Factors Revenue and Revenue Share by Type (2014-2018)
5.3. Factor I
5.3.1. Global Factor I Sales and Growth Rate (2014-2018)
5.4. Factor II
5.4.1. Global Factor II Sales and Growth Rate (2014-2018)
5.5. Factor V
5.5.1. Global Factor V Sales and Growth Rate (2014-2018)
5.6. Factor VII
5.6.1. Global Factor VII Sales and Growth Rate (2014-2018)
5.7. Factor X
5.7.1. Global Factor X Sales and Growth Rate (2014-2018)
5.8. Factor XI
5.8.1. Global Factor XI Sales and Growth Rate (2014-2018)
5.9. Factor XIII
5.9.1. Global Factor XIII Sales and Growth Rate (2014-2018)
6. Rare Hemophilia Factors Market, By Treatment
6.1. Introduction
6.2. Global Rare Hemophilia Factors Sales, Revenue and Market Share by Treatment (2014-2018)
6.2.1. Global Rare Hemophilia Factors Sales and Sales Share by Treatment (2014-2018)
6.2.2. Global Rare Hemophilia Factors Revenue and Revenue Share by Treatment (2014-2018)
6.3. Factor Concentrates
6.3.1. Global Factor Concentrates Sales and Growth Rate (2014-2018)
6.4. Modeling and Restructuring
6.4.1. Global Modeling and Restructuring Sales and Growth Rate (2014-2018)
6.5. Analytics solutions
6.5.1. Global Analytics Solutions Sales and Growth Rate (2014-2018)
6.6. Cryoprecipitate
6.6.1. Global Cryoprecipitate Sales and Growth Rate (2014-2018)
6.7. Other Treatments
6.7.1. Global Other Treatments Sales and Growth Rate (2014-2018)
7. Rare Hemophilia Factors Market, By Region
7.1. Introduction
7.2. Global Rare Hemophilia Factors Sales, Revenue and Market Share by Regions
7.2.1. Global Rare Hemophilia Factors Sales by Regions (2014-2018)
7.2.2. Global Rare Hemophilia Factors Revenue by Regions (2014-2018)
7.3. North America Rare Hemophilia Factors by Countries
7.3.1. North America Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.3.2. North America Rare Hemophilia Factors Revenue and Growth Rate (2014-2018)
7.3.3. North America Rare Hemophilia Factors Sales by Countries (2014-2018)
7.3.4. North America Rare Hemophilia Factors Revenue (Million USD) by Countries (2014-2018)
7.3.5. U.S.
7.3.5.1. United States Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.3.5.2. United States Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.3.6. Canada
7.3.6.1. Canada Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.3.6.2. Canada Rare Hemophilia Factors Sales (Millions USD) and Growth Rate (2014-2018)
7.3.7. Mexico
7.3.7.1. Mexico Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.3.7.2. Mexico Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4. Europe Rare Hemophilia Factors by Countries
7.4.1. Europe Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.2. Europe Rare Hemophilia Factors Revenue and Growth Rate (2014-2018)
7.4.3. Europe Rare Hemophilia Factors Sales by Countries (2014-2018)
7.4.4. Europe Rare Hemophilia Factors Revenue (Million USD) by Countries (2014-2018)
7.4.5. Germany
7.4.5.1. Germany Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.5.2. Germany Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4.6. UK
7.4.6.1. UK Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.6.2. UK Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4.7. France
7.4.7.1. France Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.7.2. France Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4.8. Russia
7.4.8.1. Russia Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.8.2. Russia Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4.9. Italy
7.4.9.1. Italy Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.9.2. Italy Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.4.10.2. Rest of Europe Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5. Asia-Pacific
7.5.1. Asia-Pacific Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.2. Asia-Pacific Rare Hemophilia Factors Revenue and Growth Rate (2014-2018)
7.5.3. Asia-Pacific Rare Hemophilia Factors Sales by Countries (2014-2018)
7.5.4. Asia-Pacific Rare Hemophilia Factors Revenue (Million USD) by Countries (2014-2018)
7.5.5. China
7.5.5.1. China Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.5.2. China Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5.6. Japan
7.5.6.1. Japan Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.6.2. Japan Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5.6.3.
7.5.7. Korea
7.5.7.1. Korea Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.7.2. Korea Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5.8. India
7.5.8.1. India Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.8.2. India Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5.9. Southeast Asia
7.5.9.1. Southeast Asia Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.9.2. Southeast Asia Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.5.10. Rest of Asia-Pacific
7.5.10.1. Rest of Asia-Pacific Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.5.10.2. Rest of Asia-Pacific Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.6. South America
7.6.1. South America Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.6.2. South America Rare Hemophilia Factors Revenue and Growth Rate (2014-2018)
7.6.3. South America Rare Hemophilia Factors Sales by Countries (2014-2018)
7.6.4. South America Rare Hemophilia Factors Revenue (Million USD) by Countries (2014-2018)
7.6.5. Brazil
7.6.5.1. Brazil Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.6.5.2. Brazil Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.6.6. Argentina
7.6.6.1. Argentina Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.6.6.2. Argentina Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.6.7. Columbia
7.6.7.1. Columbia Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.6.7.2. Columbia Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.6.8. Rest of South America
7.6.8.1. Rest of South America Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.6.8.2. Rest of South America Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7. Middle East and Africa
7.7.1. Middle East and Africa Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.2. Middle East and Africa Rare Hemophilia Factors Revenue and Growth Rate (2014-2018)
7.7.3. Middle East and Africa Rare Hemophilia Factors Sales by Countries (2014-2018)
7.7.4. Middle East and Africa Rare Hemophilia Factors Revenue (Million USD) by Countries (2014-2018)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.5.2. Saudi Arabia Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7.6. United Arab Emirates
7.7.6.1. United Arab Emirates Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.6.2. United Arab Emirates Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7.7. Egypt
7.7.7.1. Egypt Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.7.2. Egypt Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7.8. Nigeria
7.7.8.1. Nigeria Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.8.2. Nigeria Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7.9. South Africa
7.7.9.1. South Africa Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.9.2. South Africa Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
7.7.10. Rest of Middle East and Africa
7.7.10.1. Rest of Middle East and Africa Rare Hemophilia Factors Sales and Growth Rate (2014-2018)
7.7.10.2. Rest of Middle East and Africa Rare Hemophilia Factors Revenue (Millions USD) and Growth Rate (2014-2018)
8. Company Profiles
8.1. Novo Nordisk
8.1.1. Business Overview
8.1.2. Product Portfolio
8.1.3. Strategic Developments
8.1.4. Sales, Revenue and Market Share
8.2. Biogen
8.2.1. Business Overview
8.2.2. Product Portfolio
8.2.3. Strategic Developments
8.2.4. Sales, Revenue and Market Share
8.3. Bayer Healthcare
8.3.1. Business Overview
8.3.2. Product Portfolio
8.3.3. Strategic Developments
8.3.4. Sales, Revenue and Market Share
8.4. Pfizer, Inc.
8.4.1. Business Overview
8.4.2. Product Portfolio
8.4.3. Strategic Developments
8.4.4. Sales, Revenue and Market Share
8.5. Shire
8.5.1. Business Overview
8.5.2. Product Portfolio
8.5.3. Strategic Developments
8.5.4. Sales, Revenue and Market Share
8.6. Baxalta (Baxter Healthcare)
8.6.1. Business Overview
8.6.2. Product Portfolio
8.6.3. Strategic Developments
8.6.4. Sales, Revenue and Market Share
8.7. CSL Behring
8.7.1. Business Overview
8.7.2. Product Portfolio
8.7.3. Strategic Developments
8.7.4. Sales, Revenue and Market Share
8.8. Bio Products Laboratory Ltd.
8.8.1. Business Overview
8.8.2. Product Portfolio
8.8.3. Strategic Developments
8.8.4. Sales, Revenue and Market Share
9. Global Rare Hemophilia Factors Market Competition, by Manufacturer
9.1. Global Rare Hemophilia Factors Sales and Market Share by Manufacturer (2016-2017)
9.2. Global Rare Hemophilia Factors Revenue and Market Share by Manufacturer (2016-2017)
9.3. Global Rare Hemophilia Factors Price by Manufacturer (2016-2017)
9.4. Top 5 Rare Hemophilia Factors Manufacturer Market Share
9.5. Market Competition Trend
10. Rare Hemophilia Factors Market Forecast (2018-2023)
10.1. Global Rare Hemophilia Factors Sales, Revenue (Millions USD) and Growth Rate (2018-2023)
10.2. Rare Hemophilia Factors Market Forecast by Regions (2018-2023)
10.2.1. North America Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.1.1. United States Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.1.2. Canada Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.1.3. Mexico Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2. Europe Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.1. Germany Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.2. United Kingdom Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.3. France Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.4. Russia Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.5. Italy Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.2.6. Rest of the Europe Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3. Asia-Pacific Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.1. China Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.2. Japan Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.3. Korea Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.4. India Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.5. Southeast Asia Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.3.6. Rest of Asia-Pacific Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.4. South America Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.4.1. Brazil Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.4.2. Argentina Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.4.3. Columbia Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.4.4. Rest of South America Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5. Middle East and Africa Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.1. Saudi Arabia Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.2. UAE Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.3. Egypt Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.4. Nigeria Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.5. South Africa Rare Hemophilia Factors Market Forecast (2018-2023)
10.2.5.6. Rest of MEA Rare Hemophilia Factors Market Forecast (2018-2023)
10.3. Rare Hemophilia Factors Market Forecast by Type (2018-2023)
10.3.1. Global Rare Hemophilia Factors Sales Forecast by Type (2018-2023)
10.3.2. Global Rare Hemophilia Factors Sales Market Share Forecast by Type (2018-2023)
10.4. Rare Hemophilia Factors Market Forecast by Treatment (2018-2023)
10.4.1. Global Rare Hemophilia Factors Sales Forecast by Treatment (2018-2023)
10.4.2. Global Rare Hemophilia Factors Sales Market Share Forecast by Treatment (2018-2023)
*You can glance through the list of Tables and Figures when you view the sample copy of Rare Hemophilia Factors Market.


Table of Figures

*You can glance through the list of Tables and Figures when you view the sample copy of Rare Hemophilia Factors Market.

Request Sample

* mark fields are compulsory